ATE533472T1 - Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute - Google Patents
Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäuteInfo
- Publication number
- ATE533472T1 ATE533472T1 AT03787900T AT03787900T ATE533472T1 AT E533472 T1 ATE533472 T1 AT E533472T1 AT 03787900 T AT03787900 T AT 03787900T AT 03787900 T AT03787900 T AT 03787900T AT E533472 T1 ATE533472 T1 AT E533472T1
- Authority
- AT
- Austria
- Prior art keywords
- administration
- formulation
- solvent
- mucous
- measures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/218,989 US6946150B2 (en) | 2002-08-14 | 2002-08-14 | Pharmaceutical formulation |
| GB0218930A GB2392093B (en) | 2002-08-14 | 2002-08-14 | Pharmaceutical formulations |
| PCT/GB2003/003574 WO2004016246A1 (en) | 2002-08-14 | 2003-08-14 | Cannabinoid liquid formulations for mucosal amdinistration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533472T1 true ATE533472T1 (de) | 2011-12-15 |
Family
ID=31889678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03787900T ATE533472T1 (de) | 2002-08-14 | 2003-08-14 | Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP2314284B1 (de) |
| JP (1) | JP4515908B2 (de) |
| KR (1) | KR101008609B1 (de) |
| AT (1) | ATE533472T1 (de) |
| AU (2) | AU2003253005B2 (de) |
| CA (1) | CA2454644C (de) |
| CY (1) | CY1112523T1 (de) |
| DK (2) | DK1542657T3 (de) |
| ES (2) | ES2377819T3 (de) |
| FR (1) | FR14C0025I2 (de) |
| LU (1) | LU92233I2 (de) |
| MX (1) | MXPA05001567A (de) |
| PL (1) | PL215220B1 (de) |
| PT (2) | PT1542657E (de) |
| SI (1) | SI1542657T1 (de) |
| WO (1) | WO2004016246A1 (de) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1280515T3 (da) | 2000-03-09 | 2007-06-11 | Gw Pharma Ltd | Farmaceutiske sammensætninger omfattende cannabis |
| GB2414933B (en) * | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| AU2005305675B2 (en) * | 2004-11-16 | 2012-12-13 | Jazz Pharmaceuticals Operations Uk Limited | New use for cannabinoid |
| GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| US8980940B2 (en) | 2006-11-10 | 2015-03-17 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| US8039509B2 (en) | 2006-11-10 | 2011-10-18 | Johnson Matthey Public Limited Company | Composition comprising (−)-Δ9-trans-tetrahydrocannabinol |
| US9035130B2 (en) | 2007-05-31 | 2015-05-19 | Gw Pharma Limited | Reference plant, a method for its production, extracts obtained therefrom and their use |
| GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
| GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| GB2471523A (en) * | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2491118B (en) | 2011-05-20 | 2015-12-30 | Otsuka Pharma Co Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2496688B (en) | 2011-11-21 | 2016-06-29 | Gw Pharma Ltd | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases |
| US8741341B2 (en) * | 2012-05-07 | 2014-06-03 | Insys Therapeutics, Inc. | Manufacturing and packaging room temperature stable dronabinol capsules |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| EP3177286A4 (de) * | 2014-07-18 | 2018-05-16 | Medipath Inc. | Zusammensetzungen und verfahren zur physiologischen freisetzung von cannabidiol |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| BR122021018502B1 (pt) | 2014-10-21 | 2022-05-03 | United Cannabis Corp | Formulação de canabinoide líquida |
| EP3659605A1 (de) | 2014-12-22 | 2020-06-03 | SUDA Pharmaceuticals Ltd | Vorbeugung und behandlung von metastasenbildenden erkrankungen bei krebspatienten mit thrombozytose |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549278B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| WO2018000094A1 (en) | 2016-06-29 | 2018-01-04 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US10188628B1 (en) | 2016-10-27 | 2019-01-29 | Alvin Kershman | Release composition for derivatives of Cannabaceae |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| BR112019019966A2 (pt) | 2017-03-24 | 2020-04-28 | Trait Biosciences Inc | biossíntese in vivo de alto nível e isolamento de canabinoides solúveis em água em sistemas de plantas |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| US11905543B2 (en) | 2017-07-11 | 2024-02-20 | Trait Biosceinces, Inc. | In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures |
| US11946059B2 (en) | 2017-07-11 | 2024-04-02 | Trait Biosciences, Inc. | In vivo generation of water-soluble cannabinoids in plant cell suspension cultures |
| CN111465700A (zh) | 2017-07-11 | 2020-07-28 | 特征生物科学公司 | 在酵母和植物细胞悬浮培养物中产生水溶性大麻素化合物和材料组合物 |
| AU2018101357B4 (en) * | 2017-09-15 | 2022-03-17 | Zelira Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| MX2020003661A (es) * | 2017-11-30 | 2020-08-03 | Canopy Growth Corp | Formas de dosificacion de liquidos, metodos de fabricacion y uso. |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| EP4252778A3 (de) * | 2018-04-04 | 2023-10-18 | Vinsan Therapeutics Inc. | Topische cannabinoidformulierungen und -instillate, kits und verfahren zur behandlung von hautwunden und verwendungen davon |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| IL278548B2 (en) | 2018-05-11 | 2025-07-01 | Rhodes Tech Inc | Pharmaceutical preparations containing dronabinol and sprays containing the same pharmaceutical preparations |
| WO2019227167A1 (en) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions and treatments |
| AU2019285379A1 (en) * | 2018-06-15 | 2021-02-04 | CannPal Animal Therapeutics Limited | Cannabinoid composition and methods of treatment using the same |
| US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
| US10925853B2 (en) | 2019-04-17 | 2021-02-23 | Nordiccan A/S | Oral cannabinoid tablet |
| CN114302720A (zh) * | 2019-04-17 | 2022-04-08 | 银种马公司 | 从大麻中提取大麻素、类黄酮和萜烯 |
| US12178797B2 (en) | 2019-05-03 | 2024-12-31 | Zyus Life Sciences Inc. | Formulation for pain management |
| ES2986503T3 (es) * | 2019-05-03 | 2024-11-11 | Zyus Life Sciences Inc | Formulación para el manejo del dolor que comprende tetrahidrocannabinol (THC), cannabicromeno (CBC) y cannabidiol (CBD) en una proporción determinada |
| US12220396B2 (en) | 2019-05-03 | 2025-02-11 | Zyus Life Sciences Inc. | Formulation for pain management |
| US20220264947A1 (en) * | 2019-07-22 | 2022-08-25 | Angus RITTENBURG | Cartridge for dispensing products and methods for their manufacture |
| WO2021046189A1 (en) | 2019-09-06 | 2021-03-11 | Quicksilver Scientific, Inc. | Microemulsion delivery systems for water-based beverages |
| WO2021055937A1 (en) * | 2019-09-20 | 2021-03-25 | Good Design, Inc. | Cartridge for dispensing products and methods for their manufacture |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| AU2020358869A1 (en) | 2019-10-03 | 2022-04-14 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| EP4041209A4 (de) | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | Transdermale zusammensetzungen mit cannabidiol (cbd) zur verwendung bei der behandlung von anfallsleiden |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| CA3155181A1 (en) | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US12138241B2 (en) | 2020-07-08 | 2024-11-12 | Shaman Naturals, Llc | Compositions for preventing and treating diabetes |
| AU2021318553A1 (en) | 2020-07-28 | 2023-03-23 | Impello Biosciences Inc. | Methods and compositions for altering secondary metabolites in plants |
| JP2023546649A (ja) * | 2020-09-24 | 2023-11-07 | ニコベンチャーズ トレーディング リミテッド | 製剤 |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| AU2021386606A1 (en) | 2020-11-24 | 2023-06-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity |
| KR102489407B1 (ko) * | 2021-01-18 | 2023-01-17 | 주식회사 네이처센스 | 대마 추출물을 유효성분으로 포함하는 통증 완화 및 스트레스 관련 질환 예방 및 개선용 조성물 |
| EP4284351A1 (de) * | 2021-01-28 | 2023-12-06 | Specchiasol S.r.l. | Zusammensetzung zur behandlung schmerzhafter und/oder entzündlicher zustände |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| EP4402486A4 (de) | 2021-09-14 | 2025-09-10 | Transp Authority Inc | Systeme und verfahren zur genauen und wiederholbaren abgabe von pharmazeutischen wirkstoffen |
| AU2023321655A1 (en) | 2022-08-12 | 2025-02-13 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
| EP4483872A1 (de) * | 2023-06-30 | 2025-01-01 | Mabewo Phytopharm AG | Cannabinoidzusammensetzung zur verwendung bei der behandlung von schmerzen und/oder entzündungen |
| WO2025003517A1 (en) * | 2023-06-30 | 2025-01-02 | Mabewo Phytopharm Ag | Cannabinoid composition for use in the treatment of pain and/or inflammation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560625A (en) | 1967-02-20 | 1971-02-02 | Colgate Palmolive Co | Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system |
| DE3522550A1 (de) | 1985-06-24 | 1987-01-02 | Klinge Co Chem Pharm Fab | Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung |
| US5165093A (en) * | 1992-03-23 | 1992-11-17 | The Titan Corporation | Interstitial X-ray needle |
| GB9807639D0 (en) * | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| JP2003504321A (ja) * | 1999-07-08 | 2003-02-04 | オーランド・ハン | リポソーム被包カンナビノイドの肺送達 |
| DE19936911A1 (de) | 1999-08-05 | 2001-02-08 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| NZ517517A (en) * | 1999-08-20 | 2004-03-26 | Unimed Pharmaceuticals Inc | Composition for inhalation comprising delta-9- tetrahydrocannabinol in a semiaqueous solvent |
| GB9927555D0 (en) * | 1999-11-23 | 2000-01-19 | Bede Scient Instr Ltd | X-ray fluorescence apparatus |
| DK1280515T3 (da) * | 2000-03-09 | 2007-06-11 | Gw Pharma Ltd | Farmaceutiske sammensætninger omfattende cannabis |
| EP1361876A4 (de) * | 2001-01-26 | 2004-03-31 | Univ Connecticut | Neue cannabimimetische liganden |
| DK1361864T3 (en) | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| EP1321159A1 (de) * | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Betätigungsvorrichtung für Druckdosierinhalator mit lasergebohrten Löchern |
-
2003
- 2003-08-14 AT AT03787900T patent/ATE533472T1/de active
- 2003-08-14 WO PCT/GB2003/003574 patent/WO2004016246A1/en not_active Ceased
- 2003-08-14 AU AU2003253005A patent/AU2003253005B2/en active Active
- 2003-08-14 KR KR1020057002528A patent/KR101008609B1/ko not_active Expired - Lifetime
- 2003-08-14 PL PL375224A patent/PL215220B1/pl active Protection Beyond IP Right Term
- 2003-08-14 DK DK03787900.4T patent/DK1542657T3/da active
- 2003-08-14 JP JP2004528678A patent/JP4515908B2/ja not_active Expired - Lifetime
- 2003-08-14 EP EP10180523.2A patent/EP2314284B1/de not_active Expired - Lifetime
- 2003-08-14 EP EP03787900A patent/EP1542657B8/de not_active Expired - Lifetime
- 2003-08-14 PT PT03787900T patent/PT1542657E/pt unknown
- 2003-08-14 SI SI200332107T patent/SI1542657T1/sl unknown
- 2003-08-14 MX MXPA05001567A patent/MXPA05001567A/es active IP Right Grant
- 2003-08-14 ES ES03787900T patent/ES2377819T3/es not_active Expired - Lifetime
- 2003-08-14 PT PT101805232T patent/PT2314284T/pt unknown
- 2003-08-14 DK DK10180523.2T patent/DK2314284T3/en active
- 2003-08-14 ES ES10180523.2T patent/ES2625605T3/es not_active Expired - Lifetime
- 2003-08-14 CA CA2454644A patent/CA2454644C/en not_active Expired - Lifetime
-
2009
- 2009-06-18 AU AU2009202434A patent/AU2009202434B2/en active Active
-
2012
- 2012-02-15 CY CY20121100154T patent/CY1112523T1/el unknown
-
2013
- 2013-06-26 LU LU92233C patent/LU92233I2/fr unknown
-
2014
- 2014-03-21 FR FR14C0025C patent/FR14C0025I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT1542657E (pt) | 2012-02-29 |
| WO2004016246A1 (en) | 2004-02-26 |
| CY1112523T1 (el) | 2015-12-09 |
| EP1542657A1 (de) | 2005-06-22 |
| EP2314284A3 (de) | 2012-05-09 |
| PL375224A1 (en) | 2005-11-28 |
| MXPA05001567A (es) | 2005-04-25 |
| SI1542657T1 (sl) | 2012-04-30 |
| CA2454644C (en) | 2014-09-16 |
| EP1542657B1 (de) | 2011-11-16 |
| AU2009202434B2 (en) | 2012-08-30 |
| KR20050042157A (ko) | 2005-05-04 |
| DK1542657T3 (da) | 2012-03-05 |
| EP1542657B8 (de) | 2012-03-14 |
| JP4515908B2 (ja) | 2010-08-04 |
| ES2377819T3 (es) | 2012-04-02 |
| FR14C0025I2 (fr) | 2014-11-14 |
| JP2006504671A (ja) | 2006-02-09 |
| DK2314284T3 (en) | 2017-05-22 |
| EP2314284B1 (de) | 2017-02-15 |
| PL215220B1 (pl) | 2013-11-29 |
| EP2314284A2 (de) | 2011-04-27 |
| ES2625605T3 (es) | 2017-07-20 |
| CA2454644A1 (en) | 2004-02-14 |
| FR14C0025I1 (de) | 2014-08-08 |
| AU2009202434A1 (en) | 2009-07-09 |
| AU2003253005A1 (en) | 2004-03-03 |
| KR101008609B1 (ko) | 2011-01-17 |
| PT2314284T (pt) | 2017-05-25 |
| AU2003253005B2 (en) | 2009-03-19 |
| LU92233I2 (fr) | 2013-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE533472T1 (de) | Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute | |
| US6432415B1 (en) | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces | |
| JP5731446B2 (ja) | 局所用生体付着性製剤 | |
| MXPA03010991A (es) | Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. | |
| EP2286793A3 (de) | Cannabidiol enthaltende pharmazeutische Formulierungen | |
| ES2079210T3 (es) | Formulacion farmaceutica de aerosol. | |
| ATE398997T1 (de) | Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln | |
| EP2343045A3 (de) | System zur transmukosalen Verabreichung von Arzneimitteln | |
| BR9810729B1 (pt) | composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante. | |
| JP2003514875A (ja) | 創傷治癒を改善し、薬を投与するためのプロペラント不要のスプレー式皮膚パッチ組成物 | |
| JP2003183157A (ja) | 眼科用組成物 | |
| US11147790B2 (en) | Treatment of cutaneous disorders | |
| DE602005020317D1 (de) | Selbstemulgierendes butylbenzolphthalein-arzneimittelabgabesystem, sein herstellungsverfahren und seine anwendung | |
| ATE364391T1 (de) | Arzneiformulierung enthaltend ciclosporin und deren verwendung | |
| CL2004001325A1 (es) | Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas. | |
| KR970032872A (ko) | 아세틸살리실산을 함유하는 피부 손상 처치용 약물 | |
| BR0109747A (pt) | Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática | |
| MY126358A (en) | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs | |
| JP2005187404A (ja) | 粘膜外用噴霧組成物、点鼻剤及び口腔・咽喉疾患用剤 | |
| JP2006527764A (ja) | ジアゼパムを含有する経鼻マイクロエマルジョン | |
| WO2009070829A1 (en) | Non-aqueous oil-based fentanyl compositions for transmucosal administration | |
| JP2001039922A (ja) | ソルビン酸類の分解抑制方法及び液剤組成物 | |
| ITMI971226A1 (it) | Preparati farmaceutici topici contenenti nimesulide | |
| GEP20012464B (en) | Compositions Comprising an HIV Protease Inhibitor Such As VX 478 and a Water Soluble Vitamin E Compound Such As Vitamin E-TPGS | |
| TH59375A3 (th) | สูตรผสมทางเภสัช ที่ซึ่งการปลดปล่อยออกได้ถูกควบคุม |